Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Delcath Systems Inc (DCTH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,750
  • Shares Outstanding, K 10,300
  • Annual Sales, $ 2,720 K
  • Annual Income, $ -45,120 K
  • 36-Month Beta 0.56
  • Price/Sales 2.53
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm 6.48
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 03/15/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2300 +16.09%
on 12/20/18
0.3999 -33.23%
on 12/26/18
-0.0409 (-13.28%)
since 12/18/18
3-Month
0.2300 +16.09%
on 12/20/18
0.8500 -68.59%
on 10/22/18
-0.2930 (-52.32%)
since 10/18/18
52-Week
0.2300 +16.09%
on 12/20/18
21.5000 -98.76%
on 02/09/18
-16.2830 (-98.39%)
since 01/18/18

Most Recent Stories

More News
Biotech Stocks on the Move

HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotech has been one of the hottest sectors this month. Investors are intrigued by the increase in M&A. Now's a great time to start researching some oversold...

TCON : 0.96 (-9.43%)
TYME : 2.41 (-35.39%)
ZIOP : 2.27 (-8.47%)
DCTH : 0.2670 (+0.75%)
MNKD : 1.41 (+1.44%)
Biotech Companies to Watch

HENDERSON, NV / ACCESSWIRE / January 10, 2019 / Biotech has started 2019 off with a bang. Below are a few that you should be paying attention to.

AMRN : 17.23 (-0.17%)
DCTH : 0.2670 (+0.75%)
Biotech Stocks Set to Start 2019 Off with a Bang

HENDERSON, NV / ACCESSWIRE / January 4, 2019 / Biotech companies could be in store for a big 2019, and investors are starting to take notice. The stocks we are highlighting today all look poised for a...

CRON : 14.90 (+9.08%)
VKTX : 8.78 (+6.04%)
NVAX : 2.05 (-2.38%)
DCTH : 0.2670 (+0.75%)
CBD and Biotech Plays on The Rise

HENDERSON, NV / ACCESSWIRE / December 11, 2018 / We have found several companies releasing recent news we believe should be on your radar.

KSHB : 5.4300 (-1.45%)
MPXEF : 0.7458 (+1.84%)
DCTH : 0.2670 (+0.75%)
Growth Opportunities in Stocks Coming Off of Bottoms

HENDERSON, NV / ACCESSWIRE / November 27, 2018 / With the market in a bit of a swoon, many companies with positive 3rd quarter announcements have not yet seen them baked into the share price properly....

VKTX : 8.78 (+6.04%)
EMHTF : 2.0400 (-2.90%)
NWBO : 0.2330 (-2.88%)
OGRMF : 4.7895 (+2.01%)
DCTH : 0.2670 (+0.75%)
Delcath Announces Third Quarter Fiscal 2018 Financial Results

Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended September 30,...

DCTH : 0.2670 (+0.75%)
Delcath Announces Enrollment of First Patient in ALIGN Trial

The University of Tennessee Health Science Center, Methodist University Hospital, and West Cancer Center Begin Treatments in New Registration Trial for Intrahepatic Cholangiocarcinoma

DCTH : 0.2670 (+0.75%)
CORRECTING and REPLACING - Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma

Seven Cancer Centers in United States Open for Enrollment in Amended Trial

DCTH : 0.2670 (+0.75%)
Liver Cancers Rising - Stocks to Watch

HENDERSON, NV / ACCESSWIRE / October 5, 2018 / Liver cancer incidence has more than tripled since 1980. Liver cancer death rates have increased by almost 3% per year since 2000. More than 700,000 people...

VKTX : 8.78 (+6.04%)
ENTA : 76.90 (+3.22%)
EXEL : 22.65 (-0.74%)
DCTH : 0.2670 (+0.75%)
Multi-center Analysis of Outcomes Data on Use of Delcath CHEMOSAT in the Treatment of ICC Published in European Radiology

Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that results of a multicenter analysis of outcomes...

DCTH : 0.2670 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade DCTH with:

Key Turning Points

2nd Resistance Point 0.2733
1st Resistance Point 0.2701
Last Price 0.2670
1st Support Level 0.2637
2nd Support Level 0.2605

See More

52-Week High 21.5000
Fibonacci 61.8% 13.3749
Fibonacci 50% 10.8650
Fibonacci 38.2% 8.3551
Last Price 0.2670
52-Week Low 0.2300

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar